The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
About this item
Full title
Author / Creator
Publisher
United States: John Wiley and Sons Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley and Sons Inc
More information
Scope and Contents
Contents
Objective
Immunological studies have demonstrated a plethora of beneficial effects of dimethyl fumarate (DMF) on various cell types. However, the cellular and molecular targets are incompletely understood and response markers are scarce. Here, we focus on the relation between nuclear factor (erythroid‐derived 2)‐like 2 (NRF2) pathway induction u...
Alternative Titles
Full title
The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5989754
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5989754
Other Identifiers
ISSN
2328-9503
E-ISSN
2328-9503
DOI
10.1002/acn3.553
